Has anyone kept weight off after stopping semaglutide?

You've finished your course. The weight is creeping back. You're not imagining it.

This is the scenario that brings most people to this search. You did everything right, you were consistent, your appetite dropped, the weight came off. Then treatment ended, and three, four, six months later the number on the scale started moving in the wrong direction. It feels like a failure. It isn't.

The STEP 1 extension trial is the clearest evidence we have. Participants who lost around 15% of their body weight on semaglutide 2.4mg over 68 weeks were then observed after stopping. Within 12 months, they had regained roughly two-thirds of what they had lost. Cardiovascular risk markers that had improved during treatment largely returned to baseline too. The STEP 1 findings, published in the New England Journal of Medicine, are referenced by NICE in its guidance on semaglutide for weight management. What they show is not that the medicine stops working, it's that it is working while you take it, and biology reasserts itself when you don't.

Appetite hormones, including GLP-1, are part of the body's system for defending its weight set-point. Semaglutide mimics GLP-1 to dampen hunger signals and slow how fast the stomach empties. Stop the medicine, and hunger returns, sometimes more strongly than before treatment, at least for a period. That is physiology, not willpower.

Who tends to hold on to more of their progress

A flat answer that everyone regains everything is not accurate either. Some people maintain considerably more than the average. The pattern across trials and longer-term observational data suggests a few factors that make a difference.

Habit formation during treatment matters a lot. People who used the reduced-appetite window to genuinely change how they eat (not just eat less of the same things) tend to fare better. The appetite suppression during treatment is an opportunity to form different routines around food, portion size and eating timing. Those who treat it as a temporary restriction tend to snap back faster once the pharmacological effect lifts.

Activity levels are similarly predictive. Strength training in particular, because it preserves lean muscle mass during weight loss, means the body that emerges from treatment has a higher resting metabolic rate than one that lost the same amount of weight but mostly as muscle. If you want to know more about what affects outcomes on this medicine, the Wegovy treatment page covers the evidence in more depth.

There is also the question of what drove the excess weight in the first place. For some people, a single sustained course of treatment combined with lasting behaviour change is enough. For others, excess weight is driven by ongoing biological factors that will reassert themselves without continued medical support, in the same way you would not expect blood pressure tablets to keep working a year after stopping them.

The case for continuing treatment, and what that conversation looks like

The practical upshot of the STEP 1 extension, and the reason NICE's own appraisal of semaglutide under TA875 caps NHS use at two years, is that this is a medicine that works best when it is taken. That is not an argument for staying on it indefinitely without review, it is an argument for having an honest conversation with a prescriber about what your plan is before you stop.

Options include: continuing at the maintenance dose if clinical review supports it, stepping down to a lower dose to manage tolerability or cost, taking a planned break with clear re-start criteria, or transitioning to a different approach. The decision is not one-size-fits-all. A prescriber looks at how much weight you have kept off, how long you were on treatment, your current health markers, and what your circumstances allow.

The cost of ongoing treatment is a real factor for many people, and there is no point pretending otherwise. It is worth understanding what is included in any private prescription (clinical review, aftercare support, the prescription itself) rather than comparing headline prices in isolation.

If you have a condition like rheumatoid arthritis alongside obesity, your prescriber will also factor in how weight changes interact with disease management, which adds another layer to the stopping-versus-continuing decision.

What to do if you've already stopped and the weight has returned

If treatment ended a while ago and the weight has come back, that is an extremely common situation, and a valid reason to seek a clinical review rather than assume you cannot try again. Re-starting is a clinical decision. A prescriber would want to understand what happened last time, what changed when treatment stopped, and whether the approach needs to differ.

Our clinical team reviews every consultation personally. There is no algorithm making that call. If you tried semaglutide previously and want to understand your options now, the starting point is a fresh assessment: your health has likely changed, and the clinical picture needs to be looked at as it stands today, not as it was when you first started.

It is also worth knowing that not everyone responds to semaglutide in the same way, and eligibility criteria for weight-loss medicines are broader than many people expect. If you are unsure whether you would qualify, who can take Wegovy for weight loss explains the licensed criteria clearly.

Speak to our prescribers if you want an honest assessment of where you are now and what the realistic options look like. That conversation is free, and the review is done the same day.